knowledge -WSS

knowledge

author：comprehensive 2025-10-04 07:02:24 Page View：26

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 5 dead in mass shooting on Caribbean island of St. Vincent: Police
Next article： After affirmative action ruling, medical educators look to 'holistic review'

knowledge

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

AdobeExpertadviserstotheFoodandDrugAdministrationonFridayvotedunanimouslyinfavorof expandingtheappro

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

When a patient nears the end, a feared therapy can comfort

ArmellaLeungforSTATItwasmid-October2008whenthemedicsrolledtheelderlymanthroughtheglass-enclosedlobby

knowledge

leisure time

knowledge

When a patient nears the end, a feared therapy can comfort